Quick Takeaways
- ERAS - Erasca, Inc. has 14 insiders with reported activity on this page.
- Net insider value flow over the last year: -$2,283,572.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 14 Insiders of Erasca, Inc.
- Symbol
- ERAS on Nasdaq
- Location
- San Diego, CA
What Changed
- Buy value: ; sell value: $2,283,572.
- Net share flow: -220,000.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$2,283,572.
Buys
$0
Shares: 0
Insiders: 0
Sells
$2,283,572
Shares: 220,000
Insiders: 2
Net
-$2,283,572
Shares: -220,000
Insiders: -2
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 100,000 | $0 | $1,612,760 | -$1,612,760 |
| 3-6 | 0 | 120,000 | $0 | $670,812 | -$670,812 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Erasca, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| ARCH Venture Partners X, LLC | 10%+ Owner | $17,572,804 | Mixed | 20 Jul 2021 | ||
| Bihua Chen | Director | $17,187,655 | Mixed | 22 Jun 2023 | ||
| Wei Lin | Chief Medical Officer | $501,983 | Mixed | 01 Feb 2023 | ||
| Ebun Garner | Chief Legal Officer | $411,246 | -$1,982,812 | -83% | Filing P/S | 01 Apr 2026 |
| David M. Chacko | CFO and CBO | $334,380 | Mixed | 15 Dec 2025 | ||
| Pratik S. Multani | Director | $257,570 | Mixed | 01 Jan 2026 | ||
| Shannon Morris | Chief Medical Officer | $0 | -$300,760 | -100% | Mixed | 04 Mar 2026 |
| James Arthur Bristol | Director | Mixed | 01 Jan 2026 | |||
| Michael David Varney | Director | Mixed | 29 Jan 2026 | |||
| Valerie Denise Harding Start | Director | Mixed | 01 Jan 2026 | |||
| Jean I. Liu | Director | Mixed | 01 Jan 2026 | |||
| Julie Hambleton | Director | Mixed | 24 Jun 2025 | |||
| Jonathan E. Lim | Chairman & CEO, Director, 10%+ Owner | Mixed | 29 Jan 2026 | |||
| Alexander W. Casdin | Director | Mixed | 01 Jan 2026 |
Top shareholders of Erasca, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
|
Company |
5.7%
|
16,111,414
|
$108,913,159 | -$28,532,250 | 31 Dec 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
8%
|
22,729,436
|
$84,553,502 | — | 31 Dec 2025 | |
| VR Adviser, LLC |
13F
|
Company |
6.3%
|
17,857,083
|
$66,428,349 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5.5%
|
15,597,330
|
$58,022,066 | — | 31 Dec 2025 | |
| Paradigm Biocapital Advisors LP |
13D/G
13F
|
Company |
5.3%
|
15,159,095
|
$56,391,833 | $0 | 07 Jan 2026 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
13D/G
|
Company |
5.1%
from 13D/G
|
14,502,004
|
$53,947,455 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13F
13D/G
|
Company |
4.8%
from 13D/G
|
13,000,000
|
$48,360,000 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.5%
|
12,812,156
|
$47,661,220 | — | 31 Dec 2025 | |
| ARCH Venture Management, LLC |
13F
|
Company |
3.9%
|
11,055,554
|
$41,126,661 | — | 31 Dec 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
3.3%
|
9,273,428
|
$34,497,152 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
3.1%
|
8,757,249
|
$32,576,966 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.2%
|
6,174,642
|
$22,969,668 | — | 31 Dec 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
— |
5.3%
|
15,038,753
|
$21,355,029 | -$10,702,679 | 30 Jun 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
1.9%
|
5,405,404
|
$20,108,103 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
4,926,335
|
$18,330,444 | — | 31 Dec 2025 | |
| ARCH Venture Partners X, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
11,055,554
|
$17,572,804 | — | 20 Jul 2021 | |
| Bihua Chen |
3/4/5
|
Director |
—
mixed-class rows
|
10,873,246
mixed-class rows
|
$17,187,655 | — | 22 Jun 2023 | |
| NOVARTIS PHARMA AG |
13D/G
|
— |
4.4%
|
12,307,692
|
$17,107,692 | $0 | 31 Dec 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
1.4%
|
3,900,000
|
$14,508,000 | — | 31 Dec 2025 | |
| Spruce Street Capital LP |
13F
|
Company |
1.4%
|
3,889,632
|
$14,469,431 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
3,331,418
|
$12,392,875 | — | 31 Dec 2025 | |
| a16z Capital Management, L.L.C. |
13F
|
Company |
1%
|
2,862,500
|
$10,648,500 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.79%
|
2,237,951
|
$8,325,178 | — | 31 Dec 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.76%
|
2,162,162
|
$8,043,243 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.68%
|
1,930,642
|
$7,181,988 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.63%
|
1,775,685
|
$6,602,155 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.59%
|
1,673,404
|
$6,225,063 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.57%
|
1,611,850
|
$5,996,083 | — | 31 Dec 2025 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.53%
|
1,490,967
|
$5,546,397 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.47%
|
1,331,508
|
$4,953,210 | — | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.47%
|
1,317,584
|
$4,901,412 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.41%
|
1,153,090
|
$4,289,495 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.36%
|
1,030,345
|
$3,832,883 | — | 31 Dec 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.34%
|
951,710
|
$3,540,361 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.32%
|
912,519
|
$3,394,571 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.32%
|
900,000
|
$3,348,000 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.3%
|
850,100
|
$3,162,372 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.29%
|
810,385
|
$3,014,632 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.26%
|
735,396
|
$2,735,673 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.24%
|
669,876
|
$2,491,939 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.19%
|
546,776
|
$2,034,007 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.19%
|
543,196
|
$2,020,690 | — | 31 Dec 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.19%
|
536,909
|
$1,997,000 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
0.18%
|
521,455
|
$1,939,813 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.15%
|
424,713
|
$1,579,932 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.14%
|
402,796
|
$1,498,401 | — | 31 Dec 2025 | |
| Creative Planning |
13F
|
Company |
0.14%
|
381,695
|
$1,419,905 | — | 31 Dec 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.12%
|
346,072
|
$1,287,387 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.12%
|
329,795
|
$1,226,837 | — | 31 Dec 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.09%
|
258,275
|
$960,783 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Erasca, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Ebun Garner | ERAS | Common Stock | Sale | -76.1% | $1,312,000 | $16.40 | -80,000 | 25,076 | 01 Apr 2026 | Direct |
| Ebun Garner | ERAS | Common Stock | Options Exercise | 319% | 80,000 | 105,076 | 01 Apr 2026 | Direct | ||
| Ebun Garner | ERAS | Stock Option (right to buy) | Options Exercise | -22.2% | -80,000 | 280,000 | 01 Apr 2026 | Direct | ||
| Shannon Morris | ERAS | Common Stock | Sale | -100% | $300,760 | $15.04 | -20,000 | 0 | 04 Mar 2026 | Direct |
| Shannon Morris | ERAS | Common Stock | Options Exercise | 20,000 | 20,000 | 04 Mar 2026 | Direct | |||
| David M. Chacko | ERAS | Stock option (right to buy) | Award | 640,000 | 640,000 | 29 Jan 2026 | Direct | |||
| Shannon Morris | ERAS | Stock option (right to buy) | Award | 625,000 | 625,000 | 29 Jan 2026 | Direct | |||
| Michael David Varney | ERAS | Stock option (right to buy) | Award | 96,000 | 96,000 | 29 Jan 2026 | Direct | |||
| Ebun Garner | ERAS | Stock option (right to buy) | Award | 560,000 | 560,000 | 29 Jan 2026 | Direct | |||
| Jonathan E. Lim | ERAS | Stock option (right to buy) | Award | 2,000,000 | 2,000,000 | 29 Jan 2026 | Direct | |||
| Ebun Garner | ERAS | Common Stock | Sale | -82.7% | $670,812 | $5.59 | -120,000 | 25,076 | 07 Jan 2026 | Direct |
| Ebun Garner | ERAS | Common Stock | Options Exercise | 478.6% | 120,000 | 145,076 | 07 Jan 2026 | Direct | ||
| James Arthur Bristol | ERAS | Stock Option (right to buy) | Award | 37,762 | 37,762 | 01 Jan 2026 | Direct | |||
| Jean I. Liu | ERAS | Stock Option (right to buy) | Award | 20,617 | 20,617 | 01 Jan 2026 | Direct | |||
| Pratik S. Multani | ERAS | Stock Option (right to buy) | Award | 19,532 | 19,532 | 01 Jan 2026 | Direct | |||
| Valerie Denise Harding Start | ERAS | Stock Option (right to buy) | Award | 24,306 | 24,306 | 01 Jan 2026 | Direct | |||
| Alexander W. Casdin | ERAS | Stock Option (right to buy) | Award | 23,872 | 23,872 | 01 Jan 2026 | Direct | |||
| David M. Chacko | ERAS | Common Stock | Other | 6.79% | 17,793 | 279,980 | 15 Dec 2025 | Direct | ||
| Ebun Garner | ERAS | Common Stock | Award | 18.4% | 3,902 | 25,076 | 15 Dec 2025 | Direct | ||
| Michael David Varney | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Jean I. Liu | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Julie Hambleton | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Valerie Denise Harding Start | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Pratik S. Multani | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| James Arthur Bristol | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Alexander W. Casdin | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Pratik S. Multani | ERAS | Common Stock | Gift | 6,200 | 6,200 | 23 May 2025 | By Multani Family Trust U/A DTD 08/10/2006 | |||
| Pratik S. Multani | ERAS | Common Stock | Gift | -3.59% | -6,200 | 166,666 | 23 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.